RG
IDIX

Redmile Group’s IDENIX PHARMACEUTICALS INC IDIX Stock Holding History

Redmile Group’s Portfolio IDIX Stock Details IDIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-30,200
Closed -$109K – 70
2013
Q2 		$109K Buy
+30,200
New +$124K 0.02% 47

Other funds holding IDIX

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Redmile Group's IDIX Position: Q3 2013 in Review

Redmile Group sold out of IDENIX PHARMACEUTICALS INC (IDIX) in Q3 2013, closing a stake of 30,200 shares — an estimated $109K sold.

Redmile Group first reported a position in IDIX in Q2 2013 and held it in 1 quarter. The position peaked at $109K in Q2 2013. 93 funds tracked by Wall St. Rank hold IDIX as of Q3 2013.

  • Redmile Group reported no remaining IDENIX PHARMACEUTICALS INC position as of Q3 2013 after selling out during the quarter.
  • Redmile Group sold 30,200 IDENIX PHARMACEUTICALS INC shares in Q3 2013, an estimated $109K.
  • Redmile Group first reported a position in IDENIX PHARMACEUTICALS INC in Q2 2013 and held it in 1 quarter.
  • Redmile Group's IDENIX PHARMACEUTICALS INC position peaked at $109K in Q2 2013.
  • 93 funds tracked by Wall St. Rank held IDENIX PHARMACEUTICALS INC as of Q3 2013.

Based on Redmile Group's 13F filing for Q3 2013, filed 14 Nov 2013.